Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib. METHODS: Data were pooled from patients with moderately to severely...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Arthritis Rheumatol
Päätekijät: Charles‐Schoeman, Christina, DeMasi, Ryan, Valdez, Hernan, Soma, Koshika, Hwang, Lie‐Ju, Boy, Mary G., Biswas, Pinaki, McInnes, Iain B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Rheumatoid Arthritis
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6754249/
https://ncbi.nlm.nih.gov/pubmed/31385441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40911
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia